Denali Capital Acquisition filed an investor presentation highlighting its proposed combination with Longevity Biomedical at a pro forma equity valuation of approximately $236.2 million, which assumes zero redemptions.
The SPAC has an Oct. 11 completion deadline.
Longevity is focused on advancing new technologies across therapeutics, health monitoring and digital health solutions “to increase human health span.”
As announced in January, estimated cash proceeds consist of Denali’s $85.4 million in trust. The combined company may also seek a $30 million pre-transaction PIPE. Read more.
